Publications by authors named "Y Hammoud"
Purpose: Radiotherapy quality assurance (RTQA) is essential for ensuring adherence to trial protocols. This paper summarizes the individual case review (ICR) results from the PEACE-1 trial, a phase-III study investigates standard of care (androgen deprivation therapy with or without docetaxel) with or without local radiotherapy; and with or without abiraterone acetate plus prednisone in patients with metastatic hormone-sensitive prostate cancer (mHSPC).
Materials And Methods: Participating institutions submitted radiotherapy (RT) plans for central review, assessing protocol compliance in target volume and organs at risk (OARs) delineation, as well as dose specifications.
Background: Chemoradiotherapy with high-dose cisplatin (HD-Cis: 100 mg/m q3w for three cycles) is the standard of care (SOC) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Cumulative delivered dose of cisplatin is prognostic of survival, even beyond 200 mg/m but high toxicity compromises its delivery.
Aim: Cisplatin fractionation may allow, by decreasing the peak serum concentration, to decrease toxicity.
Article Synopsis
- - The study investigates how inflammation, represented by neutrophil-to-lymphocyte ratio (NLR) and neutrophil count (PNN), impacts survival outcomes in patients with localized bladder cancer undergoing chemoradiation.
- - Analyzed data from 194 patients showed that those with high NLR (above 2.6) and elevated PNN (above 4000/mm) experienced significantly lower overall survival (OS) and progression-free survival (PFS).
- - While high PNN was a strong indicator of poor OS and PFS outcomes, NLR did not prove to be an independent prognostic factor in this analysis.
Purpose: To assess the efficacy and the tolerance of a split course hypofractionated (SCH) radiotherapy (RT) protocol in head and neck cancer (HNC) for eldery and/or unfit patients (pts).
Patients And Methods: Pts with HNC treated by SCH-RT in two institutions were included retrospectively. The main SCH RT regimen was two courses of 30 grays (Gy)/10 fractions separated by 2-4 weeks, without any systemic therapy.
Validation of diabetes medication adherence scale in the Lebanese population.
Diabetes Res Clin Pract
October 2019
Article Synopsis
- - The study aimed to validate the Diabetes Medication Adherence Scale (DMAS-7) by comparing it to another established scale (LMAS-14) and identifying factors that influence medication adherence among diabetic patients in Lebanon.
- - Conducted on 300 diabetic patients, results revealed a 33.7% adherence rate, with DMAS-7 showing good reliability and strong correlation with LMAS-14, indicating it might be a more effective tool for measuring adherence.
- - The findings suggest that achieving optimal glycated hemoglobin levels and engaging in regular physical activity significantly enhance medication adherence, making DMAS-7 a valuable resource for improving diabetes management.